GlobalData estimated that drug sales for MDD in 2019 were approximately $4.73 billion across the 8MM. The US market makes up the majority of total global sales, contributing $3.35 billion (70.7%) due to the large MDD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the MDD market will grow to be worth approximately $9.55 billion by 2029, at a compound annual growth rate (CAGR) of 7.3%. The US is expected to maintain its position as the market leader in 2029, increasing the proportion of global sales it accounts for to 84.7%
Across the 68 markets, sales in the MDD market were $8.8billion in 2019, growing to $14.4 billion in 2029. The eight major markets (US, France, Germany, Italy, Spain, UK, Japan and Canada) represent approximately 53.6% and 66.4% of 68-market sales in 2019 and 2029, respectively.
Scope of Report
Overview of major depressive disorder (MDD), including epidemiology, symptoms, diagnosis, and disease management.
Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 8MM as well as the 68M MDD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM MDD therapeutics market in the future.= and their impact on the 68M on a macro level.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Stakeholders
Table of Contents
Tables
Table 1: Major Depressive Disorder: Key Metrics in the 8MM
Table 2: DSM-V Criteria of Major Depressive Episode
Table 3: ICD-10 Criteria of Major Depressive Episode
Table 4: Subtypes of Major Depressive Episode
Table 5: Risk Factors and Comorbidities for MDD
Table 6: Treatment Guidelines for Major Depressive Disorder
Table 7: Drugs in Development for Major Depressive Disorder, 2021
Table 8: MDD Market – Global Drivers and Barriers, 2019–2029
Table 9: Key Events Impacting Sales for MDD in the US, 2019–2029
Table 10: MDD Market – Drivers and Barriers in the US, 2019–2029
Table 11: Key Events Impacting Sales for MDD in the 5EU, 2019–2029
Table 12: MDD Market – Drivers and Barriers in the 5EU, 2019–2029
Table 13: Key Events Impacting Sales for MDD in Japan, 2019–2029
Table 14: MDD Market – Drivers and Barriers in Japan, 2019–2029
Table 15: Key Events Impacting Sales for MDD in Canada, 2019–2029
Table 16: MDD Market – Drivers and Barriers in Canada, 2019–2029
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Graphs
Figure 1: Global Sales Forecast by Country for MDD in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in MDD During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of MDD During the Forecast Period
Figure 4: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
Figure 5: 8MM, 12-Month Total Prevalence of MDD (%), Men and Women, Ages ≥18 Years, 2019
Figure 6: 8MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of MDD
Figure 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD, by Severity
Figure 8: 8MM, 12-Month Total Prevalent Cases of MDD, N, Both Sexes, Ages ≥18 Years, 2019
Figure 9: 8MM, 12-Month Total Prevalent Cases of MDD by Age, N, Both Sexes, 2019
Figure 10: 8MM, 12-Month Total Prevalent Cases of MDD by Sex, N, Ages ≥18 Years, 2019
Figure 11: 8MM, Total Prevalent Cases of MDD by Severity, N, Ages ≥18 Years, 2019
Figure 12: Disease Management Model for MDD
Figure 13: MDD Treatment Algorithm
Figure 14: Unmet Needs and Opportunities in MDD
Figure 15: Overview of the Development Pipeline in Major Depressive Disorder
Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for MDD in the 8MM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of MDD During the Forecast Period
Figure 18: Competitive Assessment of the Marketed and Pipeline Drug Monotherapies Benchmarked Against the Standard of Care (SOC), Lexapro
Figure 19: Competitive Assessment of the Marketed and Pipeline Drug Adjunctive Therapies Benchmarked Against the Standard of Care (SOC), Abilify
Figure 20: Analysis of the Company Portfolio Gap in MDD During the Forecast Period
Figure 21: Global (8MM) Sales Forecast by Country for MDD in 2019 and 2029
Figure 22: Global (8MM) Sales Forecast by Drug Class for MDD in 2019 and 2029
Figure 23: Sales Forecast by Class for MDD in the US in 2019 and 2029
Figure 24: 5EU Sales Forecast by Country for MDD in 2019 and 2029
Figure 25: 5EU Sales Forecast by Class for MDD in 2019 and 2029
Figure 26: Sales Forecast by Class for MDD in Japan in 2019 and 2029
Figure 27: Sales Forecast by Class for MDD in Canada in 2019 and 2029








